Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04744831 · ClinicalTrials.gov registry record · Phase 2
Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer
A Phase 2 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 2
- Development phase
- 122
- Enrollment target
NCT04744831 is a Phase 2 study that has completed, run by Daiichi Sankyo. The registered enrollment target is 122 participants.
The verdict
NCT04744831, a Phase 2 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 122 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy, safety, and pharmacokinetics of Trastuzumab deruxtecan (T-DXd) in participants with human epidermal growth factor 2 (HER2)-overexpressing locally advanced, unresectable, or metastatic colorectal cancer (mCRC).
Interventions
- DRUG DS-8201a 5.4 mg/kg Q3W
- DRUG DS-8201a 6.4 mg/kg Q3W
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2021-03-05 |
| Est. Completion | 2024-12-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04744831
The ClinicalTrials.gov registry entry for NCT04744831 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 122 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which DS-8201a 5.4 mg/kg Q3W is the first listed.
NCT04744831 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04744831 about?
NCT04744831 is a clinical study titled "Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer". This study will evaluate the efficacy, safety, and pharmacokinetics of Trastuzumab deruxtecan (T-DXd) in participants with human epidermal growth factor 2 (HER2)-overexpressing locally advanced, unresectable, or metastatic colorectal cancer (mCRC).
What is the current status of trial NCT04744831?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 122 participants. The study started on 2021-03-05. Estimated completion is 2024-12-04.
What interventions are being tested in trial NCT04744831?
The interventions under investigation include: DS-8201a 5.4 mg/kg Q3W (DRUG), DS-8201a 6.4 mg/kg Q3W (DRUG).
Who is sponsoring clinical trial NCT04744831?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.